pISSN : 1226-4709 eISSN: 2465-8278
Open Access, Peer-reviewed
pISSN : 1226-4709 eISSN: 2465-8278
Open Access, Peer-reviewed
Young Chan Song,Kyu Joong Ahn,Hyung Ok Kim,Young Chul Kye,Jee Ho Choi,Chun Wook Park,Kwang Joong Kim
Epub 2016 February 22
Abstract
Background: Oral terbinafine, itraconazole and fluconazole are the most common agents used for the treatment of toenail onychomycosis. However, these agents differ markedly in their potential to cause clinically significant drug interactions. Triazoles such as fluconazole and itraconazole have been responsible for a greater number of clinically significant drug interactions than terbinafine.
Objective: We performed this survey to provide the information about how many patients with onychomycosis have concomitant diseases and combined medication and to gauge about the drug interaction risk of antifungal agent.
Method: The findings presented in this report are based on total 569 onychomycosis patients, with KOH positive, who visited 6 university hospitals from February 2007 to March 2007.
Result: The patients with onychomycosis had concomitant diseases (43.1%) and used combination medication (36.4%). The majority of the patient have concomitant diseases, such as hypertension (12.2%), diabetic melitus (9.5%) and hyperlipidemia (4.1%), more frequent in elderly patients. Main factor to choose antifungal agent for the cure of onychomycosis is the efficacy of the medication (55%), as well as, the safety and drug interaction risk of antifungal agent, more important in case of the patient taking a variety of concomitant drugs.
Conclusion: It is concluded that physicians should be aware of the potential interaction of the medications in order to prevent or reduce the burden of adverse events. It is required to have more cautious choice of oral antifungal agent in those patients who are taking combined medications in patients with onycomycosis.
Keywords
Combined medication Concomitant disease Fluconazole Itraconazole Onychomycosis Terbinafine
